BC Extra | Jul 31, 2019
Company News

July 31 Company Quick Takes: Bayer, Orion win approval in prostate cancer; plus Keytruda, Roche-Spark, UC v. Broad and more

Bayer, Orion androgen receptor inhibitor approved for prostate cancer  FDA approved an NDA for Nubeqa darolutamide from Bayer AG (Xetra:BAYN) and Orion Corp. (HSE:ORNAV; HSE:ORNBV) to treat non-metastatic castration-resistant prostate cancer. The oral androgen receptor...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

Earnings on deck At least 27 profitable biotechs and pharmas are slated to report earnings this week. (A) During market hours in Europe, premarket on U.S. exchanges; (B) Fiscal 1Q Company Date Pre/post mkt 2Q19...
BC Innovations | Jul 25, 2019
Product Development

The universe of universal flu vaccines

With at least 10 flu vaccines in the clinic that could confer protection against a wide range of strains, dispensing with the yearly seasonal vaccine may be in reach. Currently, seasonal flu vaccines consist of...
BC Extra | Jun 3, 2019
Company News

June 3 Company Quick Takes: EU pharmas form consortium to predict late-stage success; plus Lilly/Atomwise, Gilead/HitGen, Emergent and more

EU public-private consortium aims to better predict late-stage compounds  A group of pharmaceutical, technology and academic institutions formed a consortium to use machine learning on chemical libraries of 10 pharmaceutical companies to develop a platform...
BC Extra | May 6, 2019
Company News

May 6 Company Quick Takes: Esperion, BioMarin, WuXi AppTec, Axsome, Harbour BioMed/CTTQ, GW, Adynxx

FDA accepts Esperion NDAs for LDL-C-lowering indications  Esperion Therapeutics Inc. (NASDAQ:ESPR) gained $5 (12%) to $48.24 on Monday after FDA accepted for review a pair of NDAs for bempedoic acid (ETC-1002) and a bempedoic acid/ezetimibe...
BC Innovations | May 2, 2019
Emerging Company Profile

SAB: Human polyclonal antibodies on the hoof

SAB’s platform for producing human polyclonal antibodies directly in cows and goats avoids the limitations of other methods that start from animal or donor-derived antibodies. Therapeutic mAbs and bi- and tri-specific antibodies target no more...
BioCentury | Apr 26, 2019
Finance

Earnings on deck

Earnings on deck At least 17 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 2Q; (B) During trading hours in Europe; premarket on U.S. exchange Company Date Pre/post mkt 1Q19...
BC Extra | Apr 1, 2019
Company News

Management tracks: AACR, Acadia, Aerie

The American Association for Cancer Research inaugurated Elaine Mardis as president for 2019-20. She is the co-executive director of the Institute for Genomics Medicine at Nationwide Children’s Hospital and a professor of pediatrics at Ohio...
BioCentury | Feb 16, 2019
Finance

Earnings on deck

Earnings on deck Company Date Pre/post mkt 4Q18 EPS est 4Q17 EPS Expected chg NeoGenomics Inc. (NASDAQ:NEO) 2/19 Pre $0.05 $0.05 0% Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC) 2/20 Pre $0.84 $0.98 -14% Genmab A/S...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
Items per page:
1 - 10 of 335
BC Extra | Jul 31, 2019
Company News

July 31 Company Quick Takes: Bayer, Orion win approval in prostate cancer; plus Keytruda, Roche-Spark, UC v. Broad and more

Bayer, Orion androgen receptor inhibitor approved for prostate cancer  FDA approved an NDA for Nubeqa darolutamide from Bayer AG (Xetra:BAYN) and Orion Corp. (HSE:ORNAV; HSE:ORNBV) to treat non-metastatic castration-resistant prostate cancer. The oral androgen receptor...
BioCentury | Jul 26, 2019
Finance

Earnings on deck

Earnings on deck At least 27 profitable biotechs and pharmas are slated to report earnings this week. (A) During market hours in Europe, premarket on U.S. exchanges; (B) Fiscal 1Q Company Date Pre/post mkt 2Q19...
BC Innovations | Jul 25, 2019
Product Development

The universe of universal flu vaccines

With at least 10 flu vaccines in the clinic that could confer protection against a wide range of strains, dispensing with the yearly seasonal vaccine may be in reach. Currently, seasonal flu vaccines consist of...
BC Extra | Jun 3, 2019
Company News

June 3 Company Quick Takes: EU pharmas form consortium to predict late-stage success; plus Lilly/Atomwise, Gilead/HitGen, Emergent and more

EU public-private consortium aims to better predict late-stage compounds  A group of pharmaceutical, technology and academic institutions formed a consortium to use machine learning on chemical libraries of 10 pharmaceutical companies to develop a platform...
BC Extra | May 6, 2019
Company News

May 6 Company Quick Takes: Esperion, BioMarin, WuXi AppTec, Axsome, Harbour BioMed/CTTQ, GW, Adynxx

FDA accepts Esperion NDAs for LDL-C-lowering indications  Esperion Therapeutics Inc. (NASDAQ:ESPR) gained $5 (12%) to $48.24 on Monday after FDA accepted for review a pair of NDAs for bempedoic acid (ETC-1002) and a bempedoic acid/ezetimibe...
BC Innovations | May 2, 2019
Emerging Company Profile

SAB: Human polyclonal antibodies on the hoof

SAB’s platform for producing human polyclonal antibodies directly in cows and goats avoids the limitations of other methods that start from animal or donor-derived antibodies. Therapeutic mAbs and bi- and tri-specific antibodies target no more...
BioCentury | Apr 26, 2019
Finance

Earnings on deck

Earnings on deck At least 17 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 2Q; (B) During trading hours in Europe; premarket on U.S. exchange Company Date Pre/post mkt 1Q19...
BC Extra | Apr 1, 2019
Company News

Management tracks: AACR, Acadia, Aerie

The American Association for Cancer Research inaugurated Elaine Mardis as president for 2019-20. She is the co-executive director of the Institute for Genomics Medicine at Nationwide Children’s Hospital and a professor of pediatrics at Ohio...
BioCentury | Feb 16, 2019
Finance

Earnings on deck

Earnings on deck Company Date Pre/post mkt 4Q18 EPS est 4Q17 EPS Expected chg NeoGenomics Inc. (NASDAQ:NEO) 2/19 Pre $0.05 $0.05 0% Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC) 2/20 Pre $0.84 $0.98 -14% Genmab A/S...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
Items per page:
1 - 10 of 335